Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Kane Biotech Inc > Kane latest presentation (Dec.16th,2020) - Link
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(208)
•••
Comment by StoneMan45on Dec 30, 2020 7:06pm
117 Views
Post# 32200417

RE:RE:Kane latest presentation (Dec.16th,2020) - Link

RE:RE:Kane latest presentation (Dec.16th,2020) - Linkactually states ..."DispersinB® Wound Care biofilm wash      PMA or BLA 1st Wound Care Bioburden claims        Launching in 2022 2024 Sales projections expected to top $25M USD.."
that is 2024 (not 2025) and at current exchange rates that would be 32 million CND. The projected revenue is specific to the DispersinB Wound Care Biofilm Wash (DispersinB Wound Care Jell). The other products like the Coativ+ Surgical Gel and other DispersinB applications (prosthetic wash and other in development) would all add to this as they become available. 
Kane is an one well run company that is realizing it's potential in a rapid but methodical expansion. Happy to have found this gem

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities